Suppr超能文献

基质溶素催化结构域在2.0埃分辨率下的晶体结构:抑制剂诱导的构象变化

Crystal structure of the stromelysin catalytic domain at 2.0 A resolution: inhibitor-induced conformational changes.

作者信息

Chen L, Rydel T J, Gu F, Dunaway C M, Pikul S, Dunham K M, Barnett B L

机构信息

The Procter & Gamble Company, Health Care Research Center, Mason, OH, 45040-9462, USA.

出版信息

J Mol Biol. 1999 Oct 29;293(3):545-57. doi: 10.1006/jmbi.1999.3147.

Abstract

Matrix metalloproteinases are believed to play an important role in pathological conditions such as osteoarthritis, rheumatoid arthritis and tumor invasion. Stromelysin is a zinc-dependent proteinase and a member of the matrix metalloproteinase family. We have solved the crystal structure of an active uninhibited form of truncated stromelysin and a complex with a hydroxamate-based inhibitor. The catalytic domain of the enzyme of residues 83-255 is an active fragment. Two crystallographically independent molecules, A and B, associate as a dimer in the crystals. There are three alpha-helices and one twisted, five-strand beta-sheet in each molecule, as well as one catalytic Zn, one structural Zn and three structural Ca ions. The active site of stromelysin is located in a large, hydrophobic cleft. In particular, the S1' specificity site is a deep and highly hydrophobic cavity. The structure of a hydroxamate-phosphinamide-type inhibitor-bound stromelysin complex, formed by diffusion soaking, has been solved as part of our structure-based design strategy. The most important feature we observed is an inhibitor-induced conformational change in the S1' cavity which is triggered by Tyr223. In the uninhibited enzyme structure, Tyr223 completely covers the S1' cavity, while in the complex, the P1' group of the inhibitor displaces the Tyr223 in order to fit into the S1' cavity. Furthermore, the displacement of Tyr223 induces a major conformational change of the entire loop from residue 222 to residue 231. This finding provides direct evidence that Tyr223 plays the role of gatekeeper of the S1' cavity. Another important intermolecular interaction occurs at the active sit of molecule A, in which the C-terminal tail (residues 251-255) from molecule B inserts. The C-terminal tail interacts extensively with the active site of molecule A, and the last residue (Thr255) coordinated to the catalytic zinc as the fourth ligand, much like a product inhibitor would. The inhibitor-induced conformational change and the intermolecular C-terminal-zinc coordination are significant in understanding the structure-activity relationships of the enzyme.

摘要

基质金属蛋白酶被认为在骨关节炎、类风湿性关节炎和肿瘤侵袭等病理状况中起重要作用。基质溶解素是一种锌依赖性蛋白酶,属于基质金属蛋白酶家族。我们解析了截短的基质溶解素活性非抑制形式以及与基于异羟肟酸酯的抑制剂形成的复合物的晶体结构。该酶83 - 255位残基的催化结构域是一个活性片段。晶体中有两个晶体学独立的分子A和B,它们以二聚体形式缔合。每个分子中有三个α螺旋和一个扭曲的五链β折叠,还有一个催化锌、一个结构锌和三个结构钙离子。基质溶解素的活性位点位于一个大的疏水裂缝中。特别地,S1'特异性位点是一个深且高度疏水的腔。作为我们基于结构的设计策略的一部分,已经解析了通过扩散浸泡形成的异羟肟酸 - 磷酰胺类抑制剂结合的基质溶解素复合物的结构。我们观察到的最重要特征是抑制剂诱导的S1'腔构象变化,该变化由Tyr223触发。在非抑制酶结构中,Tyr223完全覆盖S1'腔,而在复合物中,抑制剂的P1'基团取代Tyr223以便进入S1'腔。此外,Tyr223的取代诱导了从残基222到残基231的整个环的主要构象变化。这一发现提供了直接证据,表明Tyr223起到了S1'腔守门人的作用。另一个重要的分子间相互作用发生在分子A的活性位点,分子B的C末端尾巴(残基251 - 255)插入其中。C末端尾巴与分子A的活性位点广泛相互作用,最后一个残基(Thr255)作为第四个配体与催化锌配位,很像产物抑制剂那样。抑制剂诱导的构象变化和分子间C末端 - 锌配位对于理解该酶的构效关系具有重要意义。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验